Navigation Links
Golub Capital Provides Debt Financing to Support the Acquisition of DNA Diagnostics Center, Inc. by MTS Health Investors, LLC
Date:10/21/2008

NEW YORK, Oct. 21 /PRNewswire/ -- Golub Capital today announced that it has provided a GOLD facility for the acquisition of DNA Diagnostics Center, Inc. (DDC) by MTS Health Investors, LLC (MTS). GOLD financings are proprietary Golub Capital One-Loan Debt facilities. Terms of the transaction were not disclosed.

DDC, based in Fairfield, Ohio, is one of the largest and most reputable DNA testing laboratories worldwide and the market leader in human DNA identification testing for the private sector. The Company provides a wide array of DNA testing services in the fields of biological family relationships, forensics and veterinary genetics.

DDC has achieved national recognition serving as the laboratory of choice for many national media programs including Dateline, 48 Hours and Dr. Phil, and has provided the DNA testing for numerous high-profile legal disputes. These cases include the Ohio Innocence Project, which helped exonerate Robert McClendon after 18 years of incarceration, and the landmark paternity suit that identified Larry Birkhead as the biological father of Anna Nicole Smith's daughter.

This is Golub Capital's first deal with MTS. "We are pleased to be working with MTS," said Golub Capital Principal Stefano Robertson. "Golub Capital's financial resources will help strengthen DDC's position in its unique marketplace. We are looking forward to watching DDC grow internationally."

"In this difficult economic environment it is terrific to have Golub Capital as a partner. Golub followed through with its commitment even during this volatile credit market. After working with the Golub team on closing this deal, we are confident that Golub will help us grow the company as we capitalize on opportunities within the DNA testing industry," says Kenton Rosenberry, a Managing Director with MTS.

About Golub Capital

Golub Capital underwrites and syndicates 1st lien loans up to $150 million. Our buy-and-hold products range from $5 million to $75 million and include one-loan financings (through the Firm's proprietary GOLD facility), senior, second lien and subordinated debt, preferred stock and co-investment equity. With a broad investment mandate and long-term time horizon, Golub Capital has a high level of flexibility in structuring investments. Golub Capital is a national firm. For more information, please visit http://www.golubcapital.com.


'/>"/>
SOURCE Golub Capital
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Simbionix Raises Largest Amount in Companys History in Venture Capital to Accelerate Growth
2. EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
3. Solos Endoscopy, Inc. Implements Strategy to Capitalize on $30 Billion Minimally Invasive Surgical Product Market
4. CPC of America, Inc. to Explore Strategic Alternatives; Appoints FTI Capital Advisors to Assess Potential Opportunities
5. Aerolase Retains SMH Capital Inc. to Advise on Corporate Expansion
6. Tengion Featured as Model of Innovation and Success at 35th Anniversary Celebration of the National Venture Capital Association
7. Aegis Analytical Corp. Showcases Discoverant at Inaugural Venture Capital in the Rockies Fall
8. Sinobiomed Retains CB Capital Partners as Financial Advisor to Maximize Shareholder Value
9. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
10. TVM Capital, Signet Healthcare Partners and Paul Capital Healthcare Enter into euro 26 Million Financing of SpePharm
11. MGT Capital Investments Reports Second Quarter 2008 Financial Results and Provides Update on Recent Developments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... and CAMBRIDGE, Mass. ... , Dec. 4, 2016 SystemOne, ... connected diagnostics software platforms for the developing world, ... "Anywhere. Care.™" a reality with its portable and ... entered into a development and license agreement to ...
(Date:12/2/2016)... , Dec. 2, 2016 Amgen (NASDAQ: ... today announced the submission of a Marketing Authorization Application (MAA) ... biosimilar candidate to Avastin ® (bevacizumab). The companies believe ... the EMA. "The submission of ABP 215 ... to expand our oncology portfolio," said Sean E. Harper ...
(Date:12/2/2016)... ... December 01, 2016 , ... ... findings demonstrating the value of DNA microarray comparative genomic hybridization (array CGH) ... Antonio Breast Cancer Symposium. Using molecular test results from tumors with previously ...
(Date:12/2/2016)... ... 2016 , ... DrugDev believes the only way to achieve real ... All three tenets were on display at the 2nd Annual DrugDev User Summit (hosted ... CRO and site organizations to discuss innovation and the future of clinical research. ...
Breaking Biology Technology:
(Date:12/2/2016)... Dec. 1, 2016   SoftServe , a ... BioLock , an electrocardiogram (ECG) biosensor analysis system ... key IoT asset. The smart system ensures device-to-device ... steering wheel and mobile devices to easily ,recognize, ... As vehicle technology advances, so too must ...
(Date:11/29/2016)... , Nov. 29, 2016 BioDirection, a ... point-of-care products for the objective detection of concussion and ... company has successfully completed a meeting with the U.S. ... Tbit™ blood test Pre-Submission Package. During the meeting company ... system as a precursor to commencement of a planned ...
(Date:11/28/2016)... "The biometric system market ... The biometric system market is in the growth stage ... future. The biometric system market is expected to be ... CAGR of 16.79% between 2016 and 2022. Government initiative ... in smartphones, rising use of biometric technology in financial ...
Breaking Biology News(10 mins):